Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
ISATUXIMAB-CARFILZOMIB-DEXAMETASONE (IKD) IN PATIENTS WITH MULTIPLE MYELOMA WITH RELAPSED/REFRACTORY DISEASE. REAL-LIFE RESULTS IN SEVEN SPANISH CENTERS
Isabel M. García, Dra. (she/her/hers)
Facultativo Especialista de Área en Hematología y Hemoterapia
Servicio Andaluz de Salud
Granada, Andalucia, Spain